Get the latest news, insights, and market updates on NBIX (Neurocrine Biosciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Exploring 3 High Growth Tech Stocks in the US Market
As the U.S. market experiences fluctuations with major indices like the Dow Jones and Nasdaq facing consecutive declines due to concerns over AI stock valuations, investors are closely monitoring high-growth sectors for potential opportunities. In such a dynamic environment, identifying tech stocks that demonstrate strong fundamentals and innovative capabilities can be crucial for navigating the evolving landscape of high-growth investments. Nov 18, 2025 - $NBIX
Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum
Neurocrine Biosciences (NBIX) has seen meaningful movement over the past month, drawing investor attention to its latest performance metrics. Shares have advanced 7% in the past month and are up 17% over the past year, prompting a closer look at recent business fundamentals. See our latest analysis for Neurocrine Biosciences. The recent 1-month share price return of nearly 7% for Neurocrine Biosciences comes after a strong 1-year total shareholder return of 17%. This suggests growing... Nov 13, 2025 - $NBIX
Assessing Neurocrine Biosciences After Stock Rises 7.8% and Partnership Expansion News
If you have ever wondered whether Neurocrine Biosciences is currently trading for a bargain or riding high on hype, you are in the right place. The stock has made notable moves recently, rising 2.9% over the past week and climbing 7.8% in the last 30 days. This suggests shifting investor optimism and perhaps a reevaluation of risk and growth potential. Outside of earnings reports, recent headlines have highlighted Neurocrine’s progress with its clinical trials and an expanded partnership... Nov 12, 2025 - $NBIX
Neurocrine chalks up a depression drug failure
Analysts suspected that the mid-stage trial miss wouldn't ding Neurocrine’s share price since expectations around the program were "near-zero." Nov 10, 2025 - $NBIX
3 Companies That May Be Priced Below Their Estimated Value
As the U.S. stock market rebounds from a recent tech sector downturn, major indices like the Nasdaq, Dow Jones Industrial Average, and S&P 500 have shown resilience despite ongoing economic uncertainties such as the government shutdown and trade policy debates. In this fluctuating environment, identifying stocks that may be undervalued can offer potential opportunities for investors seeking to capitalize on discrepancies between current prices and estimated intrinsic values. Nov 6, 2025 - $NBIX
How the Narrative Around Neurocrine Biosciences Is Evolving After Recent Results and Analyst Reactions
Neurocrine Biosciences has seen its fair value price target nudged upward, rising from $169.95 to $174.81 per share, following the company’s latest quarterly report. This adjustment can be traced to a mix of continued strong financial performance, cautious optimism around commercial expansion, and evolving risk perceptions. The discount rate dipped slightly to 6.87 percent. Stay tuned to learn how investors and observers can stay ahead as the story around Neurocrine’s growth prospects... Nov 5, 2025 - $NBIX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple